It will be effective to enter first generic business in the U.S. making use of strategy to avoid invalidity of patent or evasion of patent

Team manager of Boryung Pharmaceutical patent team Kim Kwang-Bum, wrote for a 'KPMA Brief' first issue (the May issue) which is released from Korean Pharmaceutical Manufacturers Association with the topic of 'Overview for the possibility of entering into U.S. generic drug market and Drug Approval-Patent Linkage System'. He suggested that generally, it is difficult to make profit with generic on...